European Society for Medical Oncology Gynaecological Cancers Congress 2023

Description

+ Include: 72 videos + 113 pdfs, size: 12.3 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

 

 

 

 

+ Topics:

ADCs in gynaecological cancers Introduction.mp4
ADCs in gynaecological cancers Q&A.mp4
ADCs in gynaecological cancers Role of ADCs in cervical cancer treatment in the era of immunotherapy.mp4
ADCs in gynaecological cancers Role of ADCs in cervical cancer treatment in the era of immunotherapy.pdf
ADCs in gynaecological cancers The evolving ADC treatment landscape in ovarian cancer.mp4
ADCs in gynaecological cancers The evolving ADC treatment landscape in ovarian cancer.pdf
ADCs in gynaecological cancers The new challenge ADC class effects, on off-target adverse reactions and their interdisciplinary management.mp4
ADCs in gynaecological cancers The new challenge ADC class effects, on off-target adverse reactions and their interdisciplinary management.pdf
ADCs in gynaecological cancers Understanding the basics Structure, key properties, mechanism of action, optimal diagnostic test to determine the target.mp4
ADCs in gynaecological cancers Understanding the basics Structure, key properties, mechanism of action, optimal diagnostic test to determine the target.pdf
AstraZeneca – Long-term survival Evidence from first-line PARPi maintenance trials.mp4
AstraZeneca – Long-term survival Integrating the latest data into clinical practice.mp4
AstraZeneca – Long-term survival Welcome and introduction.mp4
Endometrial cancer Beyond immunotherapy What is the role of HER2, p53 and other molecular targets in the recurrent.mp4
Endometrial cancer Beyond immunotherapy What is the role of HER2, p53 and other molecular targets in the recurrent.pdf
Endometrial cancer Introduction.mp4
Endometrial cancer Introduction.pdf
Endometrial cancer Is immunotherapy changing the face of recurrent metastatic endometrial cancer.mp4
Endometrial cancer Is immunotherapy changing the face of recurrent metastatic endometrial cancer.pdf
Endometrial cancer Q&A.mp4
Endometrial cancer Revisiting the adjuvant therapy in endometrial cancer ESMO Guidelines.mp4
Endometrial cancer Revisiting the adjuvant therapy in endometrial cancer ESMO Guidelines.pdf
ESMO Colloquium supported Concluding remarks.mp4
ESMO Colloquium supported Emerging molecular profiling models for advanced endometrial cancer.mp4
ESMO Colloquium supported Introduction.mp4
ESMO Colloquium supported Q&A.mp4
ESMO Colloquium supported Research insights- New immunotherapy combinations in clinical development for gynecological malignancies.mp4
ESMO Colloquium supported The landscape of approved immune checkpoint inhibitors and TKI combinations in advanced endometrial cancer.mp4
final_programme_gynae23hybrid.pdf
GSK – Shifting the treatment paradigm of OC EC Live Q&A and discussion.mp4
GSK – Shifting the treatment paradigm of OC EC Where are we going with EC- Aiming to improve outcomes in primary advanced or recurrent.mp4
GSK – Shifting the treatment paradigm of OC EC Where are we going with OC- Evolving the management of 1L.mp4
GSK – Shifting the treatment paradigm of OC EC Where are we now- Latest advances in treatment of gynecologic cancer.mp4
How hot is HIPEC treatment in ovarian cancer HIPEC is not IT (CON).pdf
How hot is HIPEC treatment in ovarian cancer Introduction and first vote.mp4
How hot is HIPEC treatment in ovarian cancer Introduction and first vote.pdf
How hot is HIPEC treatment in ovarian cancer Second vote and conclusions.mp4
How hot is HIPEC treatment in ovarian cancer Second vote and conclusions.pdf
How hot is HIPEC treatment in ovarian cancer The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO).mp4
How hot is HIPEC treatment in ovarian cancer The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO).pdf
How to interpret overall survival data with PARP inhibitors Is there a biological rationale to support decremental impact on overall survival.mp4
How to interpret overall survival data with PARP inhibitors Is there a biological rationale to support decremental impact on overall survival.pdf
How to interpret overall survival data with PARP inhibitors Is there clinical evidence to support the link between PARPi use and a negative impact on OS.mp4
How to interpret overall survival data with PARP inhibitors Is there clinical evidence to support the link between PARPi use and a negative impact on OS.pdf
How to interpret overall survival data with PARP inhibitors Q&A.mp4
How to interpret overall survival data with PARP inhibitors Why are we having this Symposium Recent regulatory actions by FDA.mp4
How to interpret overall survival data with PARP inhibitors Why are we having this Symposium Recent regulatory actions by FDA.pdf
Is cervical cancer still an orphan disease Immunotherapy in cervical cancer A paradigm shift.mp4
Is cervical cancer still an orphan disease Immunotherapy in cervical cancer A paradigm shift.pdf
Is cervical cancer still an orphan disease Innovative techniques in radiation oncology to increase cure and reduce toxicity.mp4
Is cervical cancer still an orphan disease Innovative techniques in radiation oncology to increase cure and reduce toxicity.pdf
Is cervical cancer still an orphan disease Molecular profiling and pathology of cervical cancer patients.mp4
Is cervical cancer still an orphan disease Molecular profiling and pathology of cervical cancer patients.pdf
Is cervical cancer still an orphan disease Q&A.mp4
Keynote address Introduction to the Keynote lecture.mp4
Keynote address Pandemomics Challenging assumptions in gynecologic oncology.mp4
Keynote address Pandemomics Challenging assumptions in gynecologic oncology.pdf
Mini Oral session 1MO – Identification of RAD51 foci in cancer-associated circulating cells and their association.mp4
Mini Oral session 1MO – Identification of RAD51 foci in cancer-associated circulating cells and their association.pdf
Mini Oral session 22MO – Homologous Recombination Gene Mutations in Uterine Serous Cancer.mp4
Mini Oral session 22MO – Homologous Recombination Gene Mutations in Uterine Serous Cancer.pdf
Mini Oral session 36MO – Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC).mp4
Mini Oral session 36MO – Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC).pdf
Mini Oral session 37MO – Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer.mp4
Mini Oral session 37MO – Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer.pdf
Mini Oral session 39MO – Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer.mp4
Mini Oral session 39MO – Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer.pdf
Mini Oral session 40MO – Targetable Gene Mutations in Mucinous Ovarian Cancer.mp4
Mini Oral session 40MO – Targetable Gene Mutations in Mucinous Ovarian Cancer.pdf
Mini Oral session 74MO – Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era.mp4
Mini Oral session 74MO – Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era.pdf
Mini Oral session Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO.mp4
Mini Oral session Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO.pdf
Mini Oral session Invited Discussant of abstracts 36MO and 37MO.mp4
Mini Oral session Invited Discussant of abstracts 36MO and 37MO.pdf
Mini Oral session Invited Discussant of abstracts 40MO and 74MO.mp4
Mini Oral session Invited Discussant of abstracts 40MO and 74MO.pdf
Poster Display session 10P – Neoadjuvant chemotherapy with bevacizumab for IIb stage cervical cancer.pdf
Poster Display session 11P – Conization before radical hysterectomy in early cervical cancer A Korean multi-center study.pdf
Poster Display session 12P – Tisotumab vedotin in recurrent or metastatic cervical cancer.pdf
Poster Display session 13P – Cervical cancer screening in a Basic Health Unit in South of Brazil impact of the COVID-19 pandemic.pdf
Poster Display session 14P – Clinical Outcomes Of Women Who Attend The Cameroon Baptist Convention Health Services.pdf
Poster Display session 15P – Efficacy and safety analysis of recombinant human endostatin (Endostar).pdf
Poster Display session 16P – Impact of Preoperative versus Postoperative radiotherapy and radical hysterectomy without systemic.pdf
Poster Display session 17P – Impact of adjuvant chemoradiotherapy on survival outcome compared to other treatment modalities for cervical cancer stage IIIc.pdf
Poster Display session 18P – Prospective Randomized Comparison of Quality of Life in Locally Advanced Cervical Cancer treated with Intracavitary or Interstitial Brachytherapy.pdf
Poster Display session 19P – Neoadjuvant chemotherapy followed by radical surgery vs chemoradiotherapy in patients with cervical cancer (stage IIB, FIGO 2018).pdf
Poster Display session 20P – Randomized Comparison of four Radiotherapy schedules in locally advanced cervical cancer A Prospective study.pdf
Poster Display session 21TiP – Molecular Alterations Predictive of Outcome in Early Staged Cervical Cancer.pdf
Poster Display session 23P – Pre-treatment inflammatory indexes predict the clinical outcome of patients with endometrial cancer a MITO24 study.pdf
Poster Display session 24P – A phase II trial of Docetaxel cisplatin chemotherapy followed by pelvic radiation therapy.pdf
Poster Display session 25P – Prognostic classification of endometrial cancer according to transcriptomic-based immunophenotype.pdf
Poster Display session 26P – Demographics and survival outcomes in patients (pts) with advanced or recurrent (A R) endometrial cancer (EC) in the English real-world (RW) setting.pdf
Poster Display session 27P – Treatment Outcomes and Toxicity Profiles in South Asian patients of High-Risk Endometrial Cancer treated with PORTEC-3 trial regimen.pdf
Poster Display session 28P – Clinicopathologic characteristics and oncologic outcomes of mismatch repair-deficient microsatellite instability-high endometrial cancer.pdf
Poster Display session 29P – Outcomes of patients with intermediate-high risk early stage endometrial cancer after surgery according to adjuvant treatment.pdf
Poster Display session 2P – Outcomes of patients with gynecological tumors harboring HER2 defects.pdf
Poster Display session 30P – Validation of MODEPLEX technology for the determination of POLE hotspot mutations in endometrial carcinoma samples.pdf
Poster Display session 31P – Uterine Cancer Metastasis Patterns and Racial Disparities A SEER Database Population Study 2010-2019.pdf
Poster Display session 3P – NaPi2b Expression in High Grade Serous Ovarian Cancer results from combined data sets.pdf
Poster Display session 41P – Phase 1 analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer.pdf
Poster Display session 42P – Efficacy of maintenance with PARPi in advanced ovarian cancer according to the location of BRCA mutation.pdf
Poster Display session 43P – Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC).pdf
Poster Display session 44P – Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer.pdf
Poster Display session 45P – MITO39 Effiacy and tolerability of PLD-Trabectedin in the treatment of relapsed Ovarian Cancer after maintenance therapy with PARP-i.pdf
Poster Display session 46P – Long-term residual chemotherapy-induced peripheral neuropathy (CIPN) and relationship with single nucleotides polymorphisms (SNPs).pdf
Poster Display session 47P – Platinum rechallenge (PtRc) for high-grade epithelial ovarian cancer (HGEOC) patients (pts) considered not eligible for further platinum therapy.pdf
Poster Display session 48P – Response to chemotherapy following PARP inhibition in ovarian cancer (OC) patients at Mount Vernon Cancer Centre.pdf
Poster Display session 49P – First Report on Pan-Immune-Inflammation Value as a New Prognostic Factor in Ovarian Cancer A Biomarker Analysis of OVANORDEST-1 Study.pdf
Poster Display session 4P – Evaluation of Antitumor Activity and Immunogenic Cell Death (ICD) Induction.pdf
Poster Display session 50P – Can We Learn From Failures A Systematic Review and Metanalysis of Phase III Trials in Platinum Resistant Ovarian Cancer.pdf
Poster Display session 51P – Efficacy of PARP inhibitors in patients with advanced high grade serous ovarian cancer according to BRCA domain mutations.pdf
Poster Display session 52P – Real world data of Niraparib in platinum sensitive relapsed ovarian cancer a multicenter experience of the MITO group.pdf
Poster Display session 53P – Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.pdf
Poster Display session 54P – Fallopian tube cancer and ovarian cancer A real-world comparison of epidemiological patterns, clinical outcomes, and mutational landscape.pdf
Poster Display session 55P – Evolution of Genetic Testing after Ovarian Cancer (OC) diagnosis.pdf
Poster Display session 56P – Differential response to DNA damaging agents of patients carrying the germline BRCA1 c.211 A-G pathogenic variant.pdf
Poster Display session 57P – International Ovarian Tumor Analysis (IOTA) Simple Ultrasound Rules and Risk of Malignancy Index in differentiating benign.pdf
Poster Display session 58P – The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis.pdf
Poster Display session 59P – Expression of CD47 a potent `don’t eat me’ signal’ in ovarian cancer (OC)- Correlation with other immune features and evolution under neoadjuvant.pdf
Poster Display session 5P – Physiologically relevant treatment models to investigate epigenetic mechanisms driving platinum.pdf
Poster Display session 60P – Deciphering CD8+ T-cell-related gene signatures in the tumor microenvironment to predict the immunotherapy response and prognosis.pdf
Poster Display session 61P – Fluorescent detection of epithelial cells in intraoperative flushes in ovarian cancer in the liquid biochip format.pdf
Poster Display session 62P – Development of deep learning-based auto-segmentation algorithms to diagnose and indicate peritoneal carcinomatosis lesions of ovarian cancer.pdf
Poster Display session 63P – Redefining the role of CA 19-9 as a prognostic marker in Epithelial Ovarian Cancer.pdf
Poster Display session 64P – Malignant Brenner Tumor of the Ovary- impact of adjuvant chemotherapy, age, race, laterality and stage on survival outcome.pdf
Poster Display session 65P – Clinical outcomes in ovarian clear cell carcinoma A UK single centre experience.pdf
Poster Display session 66P – PD-L1 expression following neoadjuvant chemotherapy is upregulated and serves as a prognostic factor.pdf
Poster Display session 67P – Survival and reproductive outcomes of patients with malignant ovarian germ cell tumors, a retrospective analysis.pdf
Poster Display session 68P – Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement).pdf
Poster Display session 69P – Relationship between BRCA genotype by location and duration of response to iPARP treatment. Real-life data.pdf
Poster Display session 6P – Unveiling the impact of intra-tumor heterogeneity in treatment response to achieve personalized medicine.pdf
Poster Display session 70P – Prognostic factors and outcome in ovarian adult granulosa-cell tumours a retrospective real-world data.pdf
Poster Display session 71P – survival outcomes of patients with recurrent malignant ovarian germ cell tumors, a retrospective analysis from a tertiary cancer center.pdf
Poster Display session 72TiP – AVALON Trial Phase 2b Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects with Platinum-Resistant.pdf
Poster Display session 73TiP – Niraparib maintenance in first line ovarian cancer MITO 40 an observational real-life study.pdf
Poster Display session 75P – Clinical characteristics and Desensitization protocol of Chemotherapy-induced Hypersensitivity reactions in patients with gynecologic cancer.pdf
Poster Display session 76P – To do or not to do Endometrial biopsy in younger women with abnormal uterine bleeding.pdf
Poster Display session 77P – The impact of COVID-19 on gynecological cancer diagnoses in Greece.pdf
Poster Display session 78P – Electronic tool for high grade Adverse Event (AE) reporting in gynecology (gyne) clinical trials (ClinT) at Princess Margaret Cancer Centre (PM).pdf
Poster Display session 79P – The situation of gynecological cancer before and after COVID – 19 pandemic years in Kosovo.pdf
Poster Display session 7P – Integration of whole genome sequencing (WGS) into NHS pathways for high-grade ovarian cancer (HGOC).pdf
Poster Display session 80P – Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs.pdf
Poster Display session 8P – NXP800 versus cisplatin in ARID1a-mutated Ovarian Clear Cell Carcinoma xenograft models.pdf
Poster Display session 9P – The Survival Effect And Prognost-c Factors Of Residual Tumor Conf.pdf
Proffered Paper session 32O – 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts).mp4
Proffered Paper session 32O – 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts).pdf
Proffered Paper session 33O – PRIMA ENGOT-OV26 GOG-3012 study long-term conditional PFS.mp4
Proffered Paper session 33O – PRIMA ENGOT-OV26 GOG-3012 study long-term conditional PFS.pdf
Proffered Paper session 34O – ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss.mp4
Proffered Paper session 34O – ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss.pdf
Proffered Paper session 35O – Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer.mp4
Proffered Paper session 35O – Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer.pdf
Proffered Paper session Invited Discussant of abstract 34O.mp4
Proffered Paper session Invited Discussant of abstract 34O.pdf
Proffered Paper session Invited Discussant of abstract 35O.mp4
Proffered Paper session Invited Discussant of abstract 35O.pdf
Proffered Paper session Invited Discussant of abstracts 32O and 33O.mp4
Proffered Paper session Invited Discussant of abstracts 32O and 33O.pdf
Proffered Paper session Q&A and discussion.mp4
Rare cancers Introduction.mp4
Rare cancers Is immune therapy definitely required for all clear cell carcinoma.mp4
Rare cancers Is immune therapy definitely required for all clear cell carcinoma.pdf
Rare cancers Q&A.mp4
Rare cancers State-of-the-art management in carcinosarcoma From the biology to treatment.mp4
Rare cancers State-of-the-art management in carcinosarcoma From the biology to treatment.pdf
Rare cancers Which drugs could be relevant for LGSC The present and future.mp4
Rare cancers Which drugs could be relevant for LGSC The present and future.pdf
Regeneron – VELOCISUITE- Leveraging Regeneron’s technologies to produce an innovative therapeutic pipeline.mp4
Seagen – Driving towards the future Key messages and close.mp4
Seagen – Driving towards the future Welcome and introduction.mp4
Seagen – Driving towards the future What has changed and what’s next in the 1L setting for r_m CC-.mp4
Seagen – Driving towards the future What’s new and how can we improve 2L management of r_m CC-.mp4
Welcome from the Congress Chairs Do we still need radical surgery in the PARP inhibitor era.mp4
Welcome from the Congress Chairs Do we still need radical surgery in the PARP inhibitor era.pdf
Welcome from the Congress Chairs How to select the best first line maintenance treatment.mp4
Welcome from the Congress Chairs How to select the best first line maintenance treatment.pdf
Welcome from the Congress Chairs Introduction.mp4
Welcome from the Congress Chairs New treatment in the current ovarian cancer beyond ADCs.mp4
Welcome from the Congress Chairs New treatment in the current ovarian cancer beyond ADCs.pdf
Welcome from the Congress Chairs PARP inhibitors Mechanism of resistance and how to overcome.mp4
Welcome from the Congress Chairs PARP inhibitors Mechanism of resistance and how to overcome.pdf
Welcome from the Congress Chairs Q&A.mp4
Welcome from the Congress Chairs Welcome to the ESMO Gynaecological Cancers Congress 2023.mp4
Welcome from the Congress Chairs Welcome to the ESMO Gynaecological Cancers Congress 2023.pdf